Abstract
Tacrolimus (FK506) is a new macrolide immunosuppressant isolated from Streptomyces tsukubaenesis that acts by a variety of different mechanisms, including inhibition of calcineurin. Although the mechanism of action of tacrolimus is similar to that of ciclosporin A, tacrolimus is 10 to 100 times more potent. Tacrolimus also has an effect on glucocorticoid receptor-mediated gene expression. The therapeutic efficacy of tacrolimus in primary immunosuppression has been evaluated in numerous clinical trials in patients receiving hepatic, renal, heart, lung, pancreas, intestinal, or bone marrow transplantation. Because tacrolimus displays a variety of different mechanisms of action and shows a synergism with corticosteroids, it is presumed that tacrolimus provides a new and useful therapeutic approach for autoimmune diseases, including myasthenia gravis.
Keywords: Anti-cholinesterase inhibitors, corticosteroids, immunosuppressant, FK-506 binding proteins (FKBP)-12, CYP enzyme
Current Drug Therapy
Title: Tacrolimus Treatment in Myasthenia Gravis
Volume: 2 Issue: 1
Author(s): Naoki Kawaguchi
Affiliation:
Keywords: Anti-cholinesterase inhibitors, corticosteroids, immunosuppressant, FK-506 binding proteins (FKBP)-12, CYP enzyme
Abstract: Tacrolimus (FK506) is a new macrolide immunosuppressant isolated from Streptomyces tsukubaenesis that acts by a variety of different mechanisms, including inhibition of calcineurin. Although the mechanism of action of tacrolimus is similar to that of ciclosporin A, tacrolimus is 10 to 100 times more potent. Tacrolimus also has an effect on glucocorticoid receptor-mediated gene expression. The therapeutic efficacy of tacrolimus in primary immunosuppression has been evaluated in numerous clinical trials in patients receiving hepatic, renal, heart, lung, pancreas, intestinal, or bone marrow transplantation. Because tacrolimus displays a variety of different mechanisms of action and shows a synergism with corticosteroids, it is presumed that tacrolimus provides a new and useful therapeutic approach for autoimmune diseases, including myasthenia gravis.
Export Options
About this article
Cite this article as:
Kawaguchi Naoki, Tacrolimus Treatment in Myasthenia Gravis, Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422437
DOI https://dx.doi.org/10.2174/157488507779422437 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Control of Interleukin-1β Secretion in Inflammation and Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Combinatorial Application of Multiple High-throughput Biotechnologies for the Study of Autoimmune Diseases
Current Pharmaceutical Analysis New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Role of Leptin in the Immune System
Current Immunology Reviews (Discontinued) Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science The Role of CTLA-4 Gene Polymorphisms in Autoimmune Disease Pathogenesis: A 2012 Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cholecystokinin-8 and Nerve Growth Factor: two Endogenous Molecules Working for the Upkeep and Repair of the Nervous System
Current Drug Targets - CNS & Neurological Disorders Regulatory T Cell Therapy for Type I Diabetes Targeting on β Cell Associated Autoantigens
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism CD26 / Dipeptidyl Peptidase IV: A Regulator of Immune Function and a Potential Molecular Target for Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Treatment of Central Nervous System Involvement Associated with Primary Sjogrens Syndrome
Current Pharmaceutical Design Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Inhibition of Type 1 Diabetes Development by Vitamin D Receptor Agonists
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Identification of Expressed miRNAs in Human Rheumatoid Arthritis Using Computational Approach – Discovery of a New miR-7167 from Human
MicroRNA siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety